Human CA125/MUC16 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human CA125/MUC16 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly12660-Met12923.[Accession | Q8WXI7]

分子量大小(Molecular Weight)

The protein has a predicted MW of 31.3 kDa. Due to glycosylation, the protein migrates to 50-80 kDa based on Tris-Bis PAGE result.

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

纯度(Purity)

> 95% as determined by Tris-Bis PAGE

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human CA125 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Human CA125, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human MSLN, hFc Tag with the EC50 of 1.13μg/ml determined by ELISA.

背景(Background)

MUC16, also known as the CA125 antigen, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy.Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.

分子别名(Synonyms)

CA125; CA-125; CA125MUC-16; FLJ14303; MUC16

文献(References)

(1)Das S , Batra S K. Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy[J]. Cancer Research, 2015:0008-5472.CAN-15-1050.

(2)Rao T D , Park K J , Smith-Jones P , et al. Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16[J]. Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry, 2010, 18(5):462-472.